AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01290315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Sucrose / Iron Dextran
Description: One 500 mg dose of IV iron sucrose administered over 4 hours (Cohort I), or a 750 mg dose of IV iron dextran administered as a 25 mg test dose over 5 minutes followed by a 725 mg dose over 3 hours if no adverse reaction to test dose is observed after 60 minutes (Cohort II)
Study NCT04585724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO
Study NCT04585724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study NCT00705679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir disoproxil fumarate
Description: 200 mg/300 mg tablet
Study NCT04585724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00705679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir disoproxil fumarate placebo
Description: placebo tablet
Study NCT00705679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 300 mg tablet
Study NCT04585724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Given PO
Study NCT04400188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Given PO
Study NCT04400188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given PO
Study NCT04400188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1316
Description: Given injection
Study NCT03273673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofeedback Intervention
Description: Visual and Tactile Biofeedback
Study NCT03964350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: The 0.8 g/kg body weight dose of gelatin alcohol will be divided into an average of 10 servings of 0.08 g/kg each. The 0.8 g/kg dose is equivalent to 4 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol.~The 0.4 g/kg body weight dose of gelatin alcohol will be divided into an average of 5 servings of 0.08 g/kg each. The 0.4 g/kg dose is equivalent to 2 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol.
Study NCT00705679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate placebo
Description: placebo tablet
Study NCT03964350 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo comparator will be individual servings of back cheery sugar-free jello.
Study NCT03788057 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ICS dose reduction
Description: If control of symptoms is maintained (evaluation based on clinical symptoms solely), every 3 months the dose of ICS is halved according to GINA guidelines, until the control is lost or the lowest daily dose is reached (200 mcg, calculated as budesonide equivalent).~In the case of loss of asthma control, beta-mimetic will be administered (temporarily) and return to the chronic administration of the previous, twice higher dose of ICS is restored (or further increase of treatment). In severe exacerbations, inclusion of oral steroids will be considered.
Study NCT03901131 — intervention group
Intervention type: DRUG
Intervention: Norethisterone enantate/estradiol valerate (Mesigyna, BAY98-7040)
Description: Follow clinical administration
Study NCT03564652 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Balanced energy-protein (BEP)
Description: Lactating women in the intervention arms will receive approximately 800 Kcal/day and around 16-21 gram of protein in a day in the form of ready-to-use supplement.
Study NCT03564652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: A single prophylaxis dose of 20 mg/kg in suspension form, reconstituted by trial staff before dose administration by the same.
Study NCT02314663 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COMBINED STRATEGY
Description: Participants in the intervention group will be supplied with: a) printed matter containing information on the disease and its management (this will be handed out at each of the follow-up visits); b) mobile-telephone text messages containing guideline summaries, reminders of forthcoming appointments and/or arrangements for making new appointments in the event of non-attendance (in the periods between visits); and, c) self-report cards to check compliance with recommendations (across the entire follow-up).
Study NCT02803736 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Acupuncture involves the insertion of extremely thin needles through skin at strategic points on human body. Many Western practitioners view the acupuncture as a device to stimulate nerves, muscles and connective tissue, and believe that it can increases blood flow.
Study NCT02803736 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: Acupuncture involves the insertion of extremely thin needles through skin at strategic points on human body. Many Western practitioners view the acupuncture as a device to stimulate nerves, muscles and connective tissue, and believe that it can increases blood flow.
Study NCT01719796 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional analgesia infusion
Study NCT03421522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICBN preservation surgery
Description: For participants randomized to the ICBN preserving technique, surgeons will perform axillary dissection in which the second ICBN, just inferior to the axillary vein, will be preserved. Surgeons will be asked to indicate whether the ICBN nerve was fully preserved, partially preserved, or sacrificed.~All study participants will receive anesthetic management at the discretion of the attending physician, which will be documented.
Study NCT03679975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole Oral Soluble film (ROSF) 50 mg
Description: Enrolled subjects underwent an instrumental evaluation of swallowing safety before and after administration of a single dose of the ROSF formulation containing 50 mg of riluzole.
Study NCT02621112 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intradermal HBVv with imiquimod
Description: Intradermal hepatitis B vaccine with imiquimod pretreatment
Study NCT02621112 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intradermal HBVv with aqueous cream
Description: Intradermal hepatitis B vaccine with aqueous cream pretreatment
Study NCT02621112 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular HBVv with aqueous cream
Description: Intramuscular hepatitis B vaccine with aqueous cream pretreatment
Study NCT04228588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 MG [Nucala]
Description: Mepolizumab 100mg, SC, every 4 weeks
Study NCT03714724 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Intraabdominal Pressure Measurement
Description: In this method, a sterile set system (AbViser- Wolfe Tory Medical, Saik Lake City, Utah, USA) was used in normal conditions. Measurements will be made in 20 ml saline was given, Pressure transducer was used as a reset point pubic symphysis and intra-abdominal pressure was measured.
Study NCT01657175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive care
Description: The patients will be randomized to control or supportive care groups.~The control group will be given care as usual wich include clinical follow-ups at the surgical department.~The supportive care group get in addition to the clinical follow-ups a supportive care programme including:~* Discharge information about surgery and life after surgery together with their relatives.~* Active telephone contacts 1/week th first month the 2/month up to six month after discharge by a specialized nurs.~* Open telephone line were the patients can call the nursed ruing daytime. Discharge: approximately 2-4 weeks after surgery
Study NCT00580736 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Clearing
Description: Optical Clearing
Study NCT00354679 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT00354679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00705679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir 1% vaginal gel
Description: 1 gm/100 ml of 1% gel
Study NCT00705679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir placebo
Description: placebo gel
Study NCT01571401 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trying Activity for Kidney Cancer Survivors (TRACKS) Trial
Description: Participants in both arms will be provided with six individual supervised exercise sessions with a physical activity specialist that will taper to an unsupervised program by the end of the intervention. Over the 4-week period, both groups will be required to attend two sessions per week for weeks 1-2, and one session per week for weeks 3-4 at the Behavioural Medicine Fitness Centre at the University of Alberta. In order to achieve the PA guidelines established by the current public health recommendations, additional unsupervised sessions will be prescribed.
Study NCT00354679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT00354679 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: proteomic profiling
Study NCT00354679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis
Study NCT00354679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Study NCT00354679 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT00354679 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study NCT00354679 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study NCT00354679 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT04775771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal Assisted Practice
Description: The children, who were planned to be hospitalized for at least three days and were randomized to the experimental and control groups, were asked by the researcher using the face-to-face interview technique, and the questions in the patient information form were filled in on the form. Then, pre-test data were recorded by determining their anxiety levels with the State Anxiety Scale for Children, levels of fear with the Child Fear Scale, emotional and psychological well-being with the Stirling Children's Emotional and Psychological Well-being Scale. Unlike the other scales, the anxiety levels were assessed twice with one-hour intervals on the first day with the Children's State Anxiety Scale. On the third day, the anxiety levels were evaluated twice with one-hour intervals on the first day using the State Anxiety Scale for Children. The second group, the children in the control group, had the same procedure except for the intervention; but no intervention was made.
Study NCT04338087 — intervention group
Intervention type: OTHER
Intervention: Questionnaire and personal interviews.
Description: Questionnaire and personal interviews.
Study NCT03121508 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Taking on Diabetes to Advance You (TODAY) Project
Description: This is an individualized educational intervention with activity components designed to assist in modifying habits, roles, and routines to promote healthy lifestyle patterns for individuals with type 2 diabetes.
Study NCT01837784 — intervention group
Intervention type: OTHER
Intervention: Optimization of blood pressure according to guidelines
Description: There is no specific recommendation for the intervention. The goal of the intervention is an optimization of blood pressure control. The intervention is at the discretion of the physician, but should adhere to guidelines. The intervention may therefore embrace measures such as drug prescriptions or lifestyle interventions.
Study NCT01576289 — intervention group
Intervention type: OTHER
Intervention: Histological analysis
Description: Systematic histological analysis of biopsy specimens obtained during routine endoscopic examination
Study NCT03706443 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systane Complete
Description: Lubricant eye drop which is based on propylene glycol 0.6%. Used for temporary relief of burning and irritation due to dryness of the eye.
Study NCT03706443 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systane Ultra
Description: Lubricant eye drop which is based on polyethylene glycol 400 0.4% and propylene glycol 0.3%. Used for temporary relief of burning and irritation due to dryness of the eye.
Study NCT01095432 — intervention group
Intervention type: PROCEDURE
Intervention: PWS Testing
Description: Partial wave spectroscopy (PWS)has been developed to allow scientists to learn about any changes to the cells that may indicate a risk of developing colon cancer.
Study NCT04513548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ligelizumab
Description: One injection every four weeks
Study NCT04513548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One injection every four weeks
Study NCT02596438 — intervention group
Intervention type: OTHER
Intervention: Hepatitis B
Description: Hepatitis B Surface Antigen, Hepatitis B Surface Antibody and Hepatitis B Core AB, Total Testing
Study NCT02716818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chronocort®
Description: Chronocort® is a patented oral modified release formulation of hydrocortisone which is intended to mimic, or closely match, the serum levels of endogenous cortisol.
Study NCT02716818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard glucocorticoid therapy
Description: Subjects in this arm will continue on their standard hydrocortisone therapy
Study NCT04314804 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PPP001
Description: 1 pellet smoked up to 3 times a day with titanium pipe (280 mg dried cannabis pellet - 9% THC / 2% CBD per pellet)
Study NCT04314804 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 pellet smoked up to 3 times a day with titanium pipe (280 mg dried cannabis pellet - 0% THC / 0.6% CBD per pellet)
Study NCT00139074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine fumarate
Description: oral variable dose
Study NCT00139074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate
Description: oral variable dose
Study NCT00139074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium valproate
Description: oral
Study NCT01156220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Injection, 40 mg, single dose over 5 min
Study NCT01156220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminohippurate sodium
Description: Injection, 500 mg, single dose over 5 min
Study NCT02459119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib will be packaged as 40 mg tablets in a bottle. Patients will be instructed to maintain a daily medication calendar.
Study NCT02181309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam, low dose
Study NCT02181309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam, medium dose
Study NCT02181309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meloxicam, high dose
Study NCT02181309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam, high dose
Study NCT04487912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tilmanocept
Description: Combined peri-areolar and peri-tumoral injection of 99m-Tc Tilmanocept
Study NCT04487912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nanocolloid
Description: Combined peri-areolar and peri-tumoral injection of 99m-Tc Nanocolloid
Study NCT04729413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples Counseling
Description: Psychoeducational counseling on relationships and maternal and child health in the context of HIV.
Study NCT04729413 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Enhanced Standard of Care
Description: Enhanced standard of care with education on pregnancy and postpartum health, similar to what is presented to women at routine antenatal and postpartum care.
Study NCT01119105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BC-3781
Description: BC-3781 dose 100mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
Study NCT01119105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BC-3781
Description: BC-3781 dose 150mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
Study NCT01119105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
Study NCT05080816 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral nutrition (PN)
Description: Overnight infusion of parenteral nutrition. Supplied as all-in-one-bag format. Infusion rate of 0.2 g N/kg/day.
Study NCT05080816 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enteral nutrition
Description: Oral nutrition drink. 2 \* 200 ml on the night before operation. 1\* 200 ml on the morning of operation day.
Study NCT05080816 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Overnight infusion of crystalloid fluid (Ringer acetate) infused at the same rate (ml/kg) as intervention PN
Study NCT02055781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Study NCT02055781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Therapy
Study NCT01413776 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Corn Soya Blend+
Description: A blended food consisting of corn (75-80%) and soybeans (20-25%) that has been fortified with a premix of 19 vitamins and minerals.
Study NCT00892073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide
Description: Diazoxide will be initiated at half the dose (100 mg per day) for 2 weeks to allow the insulin sensitizing action of metformin to take effect. Dosage will be increased to 200mg daily, divided twice daily with meals for 6 months.
Study NCT00892073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be initiated at 500 mg twice daily and increased to 1000 mg twice daily over a one week period to minimize gastrointestinal side effects. the 2000mg is to be taken with meals for 6 months.
Study NCT02272088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity-moderate
Description: cross -over of moderate and intense physical activity
Study NCT02272088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intense physical activity
Description: cross -over of moderate and intense physical activity
Study NCT01678105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: Treatment continued until Disease Progression, Toxicity, or patient withdrawal
Study NCT00431080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 as an IV infusion over 1h every two weeks for 4 cycles
Study NCT00431080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m2 as an IV infusion over 3hrs every two weeks for 4 cycles
Study NCT00431080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
Study NCT00431080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 700 mg/m2 IV push on day 1 every 4 weeks
Study NCT00431080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluoruracil
Description: 5-fluoruracil 700 mg/m2 IV push on day 1 every 4 weeks
Study NCT00431080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating growth factor
Description: rhG-CSF 5 μg/kg/d on days 3-10 after each cycle
Study NCT01035073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 30-60 mg daily for 8 weeks
Study NCT03318042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walnuts
Description: The group consumed a daily serving of walnuts (30 g) or 200 mL pomegranate juice for 3 days and provided a sample of urine as well as a swab specimen from the inner cheek
Study NCT03318042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pomegranate juice
Description: Those volunteers who were allergic to nuts consumed 200 mL pomegranate juice daily for 3 days and provided a sample of urine as well as a swab specimen from the inner cheek
Study NCT05631470 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MR screening
Description: This study is to compare the results of MR-FFR with pressure-wired-based FFR measurement.